MedPath

Evaluation of the effect of vitamin D consumption on the AntiTPO

Phase 2
Recruiting
Conditions
Autoimmune Hypothyroidism.
Autoimmune thyroiditis
E06.3
Registration Number
IRCT20210802052054N1
Lead Sponsor
Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
128
Inclusion Criteria

Patients of both sexes who have AntiTPO positive and their disease is approved by an endocrinologist and are in the age range of 18 to 65 years.

Exclusion Criteria

Patients who have evidence of any disease that affects the balance of the immune system, such as those with type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other autoimmune diseases.
Patients with impaired liver enzyme function
Malnourished patients
Patients with a BMI of less than 18 or more than 40.
Patients with hyperthyroidism and decreased TSH levels.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum levels of Anti TPO before and after taking vitamin D. Timepoint: Anti TPO levels are measured before the intervention and 3 and 6 months after the start of vitamin D intake. Method of measurement: After starting the study, blood samples are taken from the patients and the patients' serum is removed. Using special Anti TPO kits, the level of Anti TPO is measured by ELISA and the effect of vitamin D level on the level of Anti TPO in the serum is examined.
Secondary Outcome Measures
NameTimeMethod
Evaluation of serum vitamin D levels in patients with Anti TPO positive. Timepoint: Serum vitamin D levels are measured before the intervention and 3 and 6 months after the start of vitamin D intake. Method of measurement: After starting the study, blood samples are taken from the patients and the patients' serum is removed. Using special Vitamin D kits, the level of vitamin D is measured by ELISA.
© Copyright 2025. All Rights Reserved by MedPath